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Background: Although rates of cardiovascular (CV) events have declined over the past two decades, the burden of CV disease continues to rise 
in the US, in part due to substantial increases in type 2 diabetes (T2D) and pre-diabetes (pre-T2D) prevalence. We sought to examine trends in 
conventional and emerging CV risk factors from 1999 to 2010 in US adults with either T2D or pre-T2D, using data from the National Health and 
Nutrition Examination Survey (NHANES), a series of cross-sectional, nationally representative reviews of the US population.
methods: Trends among NHANES participants aged ≥18 years with T2D or pre-T2D in the 1999 to 2010 surveys were assessed using linear 
regression and appropriate weights to account for the complex sampling design. Selected conventional (LDL-C, HDL-C, TG, SBP, DBP) and emerging 
(non-HDL-C, hsCRP, proportion with CKD stage 3 or higher) risk factors for CV disease were analyzed. Descriptive statistics are reported.
results: The results for the analyzed CV risk factors in the first and last release cycle are shown below. 
Parameter T2D (n*=1,886) Pre-T2D (n*=5,212)
1999−2000
Release
2009−2010
Release
P† trend
1999−2010
1999−2000
Release
2009−2010
Release
P† trend
1999−2010
Conventional CV risk factor
LDL-C mg/dLmean
(95% CI)
122
(116−128)
106
(102−110)
<0.001
131
(127−135)
121
(118−124)
<0.001
HDL-C mg/dL, mean
(95% CI)
42.8
(39.7−45.8)
47.4
(46−48.9)
<0.05
47.2
(45−49.4)
52
(50.3−53.6)
<0.001
TG mg/dL, median 
(interquartile range)
188
(134-260.7)
125.3
(90.5-191.3)
<0.001
133.8 (94.3-
190.5)
110.9
(80.1−158.4)
<0.001
SBP mmHg, mean
(95% CI)
132
(129−135)
127
(124−131)
0.052
128
(127−130)
122
(121−123)
<0.001
DBP mmHg, mean
(95% CI)
71.9
(67.7−76.1)
68.2
(66.3−70.1)
<0.05
73.2
(72.1−74.4)
69.6
(68.4−70.8)
<0.001
Emerging CV risk factor
Non-HDL-C mg/dLmean
(95% CI)
167
(160−173)
139
(135−143)
<0.001
162
(158−166)
147
(144−150)
<0.001
hsCRP mg/dL, median 
(interquartile range)
0.28
(0.17−0.84)
0.30
(0.09−0.63)
0.204
0.29
(0.14−0.59)
0.19
(0.08−0.46)
<0.05
CKD Stage 3 or higher, % 4.36 (1.57-7.14)
18.09 (13.72-
22.47)
<0.002 3.52 (1.66-5.37) 6.93 (5.48-8.38) 0.268
* n = total number of participants across all 6 biannual survey releases
† P-value is for trend over the 6 biannual survey releases
conclusions: Among individuals with T2D or pre-T2D, lipid parameters and blood pressure were significantly improved over time, and hsCRP was 
reduced in the pre-T2D group. In the T2D group, the proportion with stage 3 CKD or higher increased over time. Further efforts are needed to address 
both conventional and emerging risk factors to help reduce the growing burden of CV disease in the US.
